Pharmacokinetics of cisplatin in patients receiving interleukin-2-containing treatment regimens

David R. Gandara, Edith A. Perez, Alice Denham, Valerie J. Wiebe, Michael W. DeGregorio

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Plasma cisplatin pharmacokinetics were determined in 6 patients enrolled in a phase I trial of combined high-dose cisplatin and Interleukin-2 (IL-2) therapy. Cisplatin (100 mg/m2) was given in 3% saline as a 3-h infusion on days 1 and 8 of each 28-day cycle; IL-2(2-4×106 units/m2) was given as an i.v. bolus on days 15-19 in a dose escalation trial. Peak total and ultrafiltrate plasma platinum concentrations were 1.15 and 0.172 μg/ml for cycle 1 and 1.2 and 0.124 μg/ml for cycle 3, respectively. The AUCs for total and ultrafiltrate plasma platinum were 7.33 and 0.965 μg/ml per hour for cycle 1 and 8.48 and 0.924 μg/ml per hour for cycle 3, respectively. Total body clearances for total and ultrafiltrate platinum were 0.051 and 0.525 ml/h for cycle 1 and 0.042 and 0.443 ml/h for cycle 3, respectively. These data demonstrate no significant effects of IL-2 on the plasma pharmacokinetics of cisplatin in the dose schedule given and support the feasibility of this combined modality therapy.

Original languageEnglish (US)
Pages (from-to)135-136
Number of pages2
JournalCancer Chemotherapy and Pharmacology
Volume24
Issue number2
DOIs
StatePublished - Aug 1989
Externally publishedYes

Fingerprint

Pharmacokinetics
Cisplatin
Interleukin-2
Platinum
Plasmas
Combined Modality Therapy
Therapeutics
Area Under Curve
Appointments and Schedules

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Pharmacokinetics of cisplatin in patients receiving interleukin-2-containing treatment regimens. / Gandara, David R.; Perez, Edith A.; Denham, Alice; Wiebe, Valerie J.; DeGregorio, Michael W.

In: Cancer Chemotherapy and Pharmacology, Vol. 24, No. 2, 08.1989, p. 135-136.

Research output: Contribution to journalArticle

Gandara, David R. ; Perez, Edith A. ; Denham, Alice ; Wiebe, Valerie J. ; DeGregorio, Michael W. / Pharmacokinetics of cisplatin in patients receiving interleukin-2-containing treatment regimens. In: Cancer Chemotherapy and Pharmacology. 1989 ; Vol. 24, No. 2. pp. 135-136.
@article{3f7de737f2464e6197ee4f3025c3b548,
title = "Pharmacokinetics of cisplatin in patients receiving interleukin-2-containing treatment regimens",
abstract = "Plasma cisplatin pharmacokinetics were determined in 6 patients enrolled in a phase I trial of combined high-dose cisplatin and Interleukin-2 (IL-2) therapy. Cisplatin (100 mg/m2) was given in 3{\%} saline as a 3-h infusion on days 1 and 8 of each 28-day cycle; IL-2(2-4×106 units/m2) was given as an i.v. bolus on days 15-19 in a dose escalation trial. Peak total and ultrafiltrate plasma platinum concentrations were 1.15 and 0.172 μg/ml for cycle 1 and 1.2 and 0.124 μg/ml for cycle 3, respectively. The AUCs for total and ultrafiltrate plasma platinum were 7.33 and 0.965 μg/ml per hour for cycle 1 and 8.48 and 0.924 μg/ml per hour for cycle 3, respectively. Total body clearances for total and ultrafiltrate platinum were 0.051 and 0.525 ml/h for cycle 1 and 0.042 and 0.443 ml/h for cycle 3, respectively. These data demonstrate no significant effects of IL-2 on the plasma pharmacokinetics of cisplatin in the dose schedule given and support the feasibility of this combined modality therapy.",
author = "Gandara, {David R.} and Perez, {Edith A.} and Alice Denham and Wiebe, {Valerie J.} and DeGregorio, {Michael W.}",
year = "1989",
month = "8",
doi = "10.1007/BF00263136",
language = "English (US)",
volume = "24",
pages = "135--136",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Pharmacokinetics of cisplatin in patients receiving interleukin-2-containing treatment regimens

AU - Gandara, David R.

AU - Perez, Edith A.

AU - Denham, Alice

AU - Wiebe, Valerie J.

AU - DeGregorio, Michael W.

PY - 1989/8

Y1 - 1989/8

N2 - Plasma cisplatin pharmacokinetics were determined in 6 patients enrolled in a phase I trial of combined high-dose cisplatin and Interleukin-2 (IL-2) therapy. Cisplatin (100 mg/m2) was given in 3% saline as a 3-h infusion on days 1 and 8 of each 28-day cycle; IL-2(2-4×106 units/m2) was given as an i.v. bolus on days 15-19 in a dose escalation trial. Peak total and ultrafiltrate plasma platinum concentrations were 1.15 and 0.172 μg/ml for cycle 1 and 1.2 and 0.124 μg/ml for cycle 3, respectively. The AUCs for total and ultrafiltrate plasma platinum were 7.33 and 0.965 μg/ml per hour for cycle 1 and 8.48 and 0.924 μg/ml per hour for cycle 3, respectively. Total body clearances for total and ultrafiltrate platinum were 0.051 and 0.525 ml/h for cycle 1 and 0.042 and 0.443 ml/h for cycle 3, respectively. These data demonstrate no significant effects of IL-2 on the plasma pharmacokinetics of cisplatin in the dose schedule given and support the feasibility of this combined modality therapy.

AB - Plasma cisplatin pharmacokinetics were determined in 6 patients enrolled in a phase I trial of combined high-dose cisplatin and Interleukin-2 (IL-2) therapy. Cisplatin (100 mg/m2) was given in 3% saline as a 3-h infusion on days 1 and 8 of each 28-day cycle; IL-2(2-4×106 units/m2) was given as an i.v. bolus on days 15-19 in a dose escalation trial. Peak total and ultrafiltrate plasma platinum concentrations were 1.15 and 0.172 μg/ml for cycle 1 and 1.2 and 0.124 μg/ml for cycle 3, respectively. The AUCs for total and ultrafiltrate plasma platinum were 7.33 and 0.965 μg/ml per hour for cycle 1 and 8.48 and 0.924 μg/ml per hour for cycle 3, respectively. Total body clearances for total and ultrafiltrate platinum were 0.051 and 0.525 ml/h for cycle 1 and 0.042 and 0.443 ml/h for cycle 3, respectively. These data demonstrate no significant effects of IL-2 on the plasma pharmacokinetics of cisplatin in the dose schedule given and support the feasibility of this combined modality therapy.

UR - http://www.scopus.com/inward/record.url?scp=0024397228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024397228&partnerID=8YFLogxK

U2 - 10.1007/BF00263136

DO - 10.1007/BF00263136

M3 - Article

C2 - 2786459

AN - SCOPUS:0024397228

VL - 24

SP - 135

EP - 136

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -